HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Programmed cell death 1 ligand 1 (PD-L1) shields tumors from immune attack.
• Immune checkpoint blockade (ICB) therapies show promise but face resistance.
• Understanding PD-L1 regulation is crucial for improving cancer treatments.

Purpose of the Study:

• To elucidate the molecular mechanisms regulating PD-L1 stability and degradation.
• To investigate the role of HIP1R in PD-L1 lysosomal trafficking.
• To develop a novel therapeutic strategy targeting PD-L1 degradation.

Main Methods:

• Co-immunoprecipitation assays to confirm HIP1R-PD-L1 interaction.
• Immunofluorescence microscopy to track PD-L1 localization.
• CRISPR-mediated gene depletion of HIP1R in tumor cells.
• In vitro cytotoxicity assays.
• Design and synthesis of a chimeric peptide (PD-LYSO).

Main Results:

• HIP1R directly binds to PD-L1 and mediates its lysosomal degradation via a lysosomal targeting signal.
• HIP1R depletion leads to PD-L1 accumulation and reduced T cell-mediated cytotoxicity.
• The PD-LYSO peptide effectively reduces PD-L1 expression in tumor cells.
• Targeted PD-L1 degradation by PD-LYSO enhances anti-tumor immune responses.

Conclusions:

• HIP1R is a key regulator of PD-L1 lysosomal degradation.
• Targeting HIP1R-mediated PD-L1 degradation offers a novel therapeutic avenue.
• The chimeric peptide PD-LYSO demonstrates potential for cancer immunotherapy.